Shares of California-based Dermata Therapeutics, Inc. (DRMA), are up more than 5 percent in pre-market after it announced positive topline results from phase 1b clinical trial of DMT310, its lead product candidate for the treatment of mild-to-moderate Psoriasis.
from RTT - Before the Bell https://ift.tt/3vovVhU
via IFTTT
No comments:
Post a Comment